Accenture Technology Vision 2012

Industry Series

Life Sciences

Technology Vision 2012: What it means for Life Sciences
High performing companies master technology trends to keep ahead of their competitors and getting ahead of disruptive technologies has become critical to responding to the unique challenges in our industry and taking new opportunities.

Life sciences companies face unprecedented challenges as revenues come under pressure as a consequence of pricing pressures caused by healthcare reforms and austerity measures, increased competition, and challenges in bringing new drugs and other products to market. They are responding by focusing on growth opportunities in emerging markets, pursuing breakthrough innovation through collaboration with industry and academic partners, challenging and revolutionizing the traditional sales and marketing and R&D operating models and focusing on operational efficiency. Shifts in the behavior of patients and healthcare professionals and emerging technologies are changing the relationship life sciences companies have with their traditional customers and creating new opportunities for collaboration, which will have a fundamental impact on the future success of businesses. Accenture’s annual Technology Vision report provides a perspective on the future of technology beyond the current conversations about the cloud, mobility, and big data. This year’s report—Technology Vision 20121—outlines the new technology trends that forward-thinking technology leaders will master to position their organizations to drive growth, while continuing to focus on cost-cutting and efficiency improvements. This paper gives Accenture’s view of how these technology trends in 2012 present opportunities for forward-thinking technology leaders in the life sciences industry.

Accenture has identified six cross industry technology trends that will influence life sciences over the next three to five years: 1.  Context-based services Where you are and what you are doing will drive the next wave of digital services. 2.  Converging data architectures Rebalancing the data architecture portfolio and blending the structured with the unstructured are key to turning data into new streams of value. 3.  Industrialized data services The ability to share data will make it more valuable but organizations will need to rise to the challenge of managing it differently from the past. 4.  Social-driven IT Social will move well beyond a bolt-on marketing channel to being an integral enabler of the next generation of collaboration for Life Sciences companies both within their organizations, and outside as part of the broader Life Sciences ecosystem. 5.  PaaS-enabled agility The maturing platform-as-a-service (PaaS) market will shift the emphasis from cost-cutting to business innovation, supporting rapid evolution for business processes that need continual change. 6.  Orchestrated analytical security Organizations will have to accept that their gates will be breached and begin preparing their second line of defense—data platforms—to mitigate the damage caused by attacks that get through.

2

Technology Vision 2012 What it means for Life Sciences Aligning life sciences industry trends with emerging technologies for strategic advantage INDUSTRY CHALLENGES Pricing pressures caused by healthcare reform and austerity measures Increased regulatory barriers/decrease in R&D productivity TECHNOLOGY SUPPORTED RESPONSES Services beyond the pill or medical device Patient outcomedriven healthcare provision Precision or personalized medicines and diagnostics Data standards. and governance Increased competition. roles. services. patent expiries and generics Drive internal innovation Context-Based Services Converging Data Architectures Industrialized Data Services Reduce G&A costs and increase productivity through outsourcing TECHNOLOGY TRENDS Customer listening and engagement Social-Driven IT PaaS-Enabled Agility Orchestrated Analytical Security New collaboration models with industry and academia New global/local op models for digital content production and distribution Multi channel sales and marketing Move to variable cost model leveraging cloud Acquisition and collaboration engine Globalization/shift to emerging markets Changing customer expectations INDUSTRY OPPORTUNITIES Life science ecosystem evolution 3 .

social media. suggesting changes in behavior.. Boehringer Ingelheim is piloting a program to tackle issues and modify behaviors in type 2 diabetes patients by providing them with information. provides emergency responders with additional information that will help them provide assistance. For example.5 Adherence is monitored through biometric feedback—for example. location data and other types of contextual input. and. which provides information on local pollen count and details of nearby medication availability. real-time insight (see sidebar). Patient response to aspects of the program also gives clues as to which parts of the program work and which need modification to suit common behavior. Technologyenabled personal devices (e. Context-based services.g. have helped life sciences companies find ways to engage with patients and provide them with useful services.g. timely and focused on patient outcomes. and the public restroom app launched by Pfizer in Israel to help in that company’s campaign to raise awareness of overactive bladder as a condition and provide advice and helpline access. through the patient’s wireless glucose meter. tablets and smart phones with Bluetooth 4.Technology Vision 2012 What it means for Life Sciences Context-based services will engage patients and healthcare professionals with new digital services Location-based capabilities. profile knowledge.e. heart monitors. The ability of devices to “talk to each other” increases the potential for contextual information to play a key role in supporting the patient beyond the pill. services that combine realtime signals from the physical world with online activities. if necessary. glucose meters) to unobtrusively collect information on a patient’s health conditions.0) can sync with intelligent medical devices (e. the first comprehensive location-management system designed specifically for Alzheimer’s patients and their caregivers.. 4 . incentives. Accenture partnered with the Alzheimer’s Association to build a business model for Comfort Zone. where necessary. Comfort Zone proactively communicates the location of the subject and.2 Context-based capabilities are now being used to fundamentally improve the quality of life for some groups of patients. This opens up a whole world of potential for life sciences companies to provide services that improve outcomes for patients.4 As an example. It also has the potential to change traditional approaches to research and development (R&D) and help bring products to market more quickly by extending the ability for trial participants to take part in “in-life trials” from their homes. enabled by wide-scale smart phone and 3G/4G availability. i. will provide customer relevant data allowing life sciences companies to provide enhanced health solutions that are relevant. Notable examples include the Clarityn app.3 The custom-designed monitoring solution integrates electronic patient-tracking devices with advanced location-tracking platforms from Omnilink to improve home care and reduce the overall cost of care for those suffering from Alzheimer’s disease. The new generation of wireless sensors will be able to provide more sophisticated.

companies will be able to further improve sales reps’ productivity and the quality of the reps’ interactions with healthcare professionals. Technology leaders should be driving the discussion with business colleagues on the value of context and setting up an environment that supports an experimental approach. including dynamic call scheduling and route planning. The devices could “talk” and auto-generate an emergency call to a previously specified healthcare provider. A sales representative can already use integrated technologies to prepare for a sales visit. Imagine a scenario in which a heart-rate monitor could send information regarding erratic heartbeats to a technology-enabled smart phone. They should also think about forming innovative partnerships with device and network providers. The sensors (or Medical Body Area Networks – MBANs) would draw power from a tiny integrated battery and use radio waves to communicate with a receiver. reduce the burden of updating call notes. and capture valuable information that the company can use as part of a sales campaign. They will be poised to offer new levels of insight that will differentiate their organization from competitors. Mobile customer-relationship management (CRM) platforms can incorporate contextual information from the sales visit to assist in follow-up actions. Scientists at GE are developing a new generation of wireless sensors that attach to the body like a Band-Aid. and their organizations.Technology Vision 2012 What it means for Life Sciences Context-based services also have significant potential to improve the effectiveness of internal teams. Technology leaders who grasp the importance of context-based connections will be able to establish themselves. By combining contextual information with real-time analytics.6 5 . as leaders. The data aggregated locally from the sensors could be relayed to doctors and hospitals with round-the-clock patient monitoring and an uninterrupted flow of data.

New technologies such as Apache Hadoop— a software framework that supports dataintensive distributed applications—have already gathered momentum. realworld data analytic capabilities required to support new business models such as health outcome analytics and personalized (or precision) medicine. The growth of companies such as Shared Health. A recent agreement between pharmacy benefit manager Medco Health Solutions and drug maker Sanofi demonstrates the benefits to be gained via such collaboration. Integrated delivery networks (IDNs) and accountable-care organizations (ACOs) are growing in number and influence in North America. life sciences companies must collaborate and align their interests with those of payers. which handles pharmacy benefits for millions of consumers through its employer and health-plan customers. The promise is a healthcare delivery system that is tuned to provide the highest-value therapeutic alternatives and therefore capable of absorbing innovations more efficiently. unstructured databases that are not only solving some old problems but also prompting us to think of new problems to solve. Real-world analytics is using the potential of Big Data to efficiently enable new business services and reimbursement models. Big Data—the catchall term for the explosion in volumes and types of data and the technologies emerging to support it—has been making big headlines. As healthcare reforms encourage focus on patient outcomes. the industry has begun the conversation about the importance of distributed data and the idea of data as a service (where data is provided on demand). deep. these technologies are providing opportunities to develop new. has rich data on these consumers’ claims. which currently holds data on 3 million patients. We are seeing patient-specific longitudinal electronic medical record (EMR) data coming together with genomic and genetic data.Technology Vision 2012 What it means for Life Sciences The ability to combine data will enable new streams of value that encourage focus on patient outcomes The scope and scale of data created and accessible exceeds the improvement in processing capacity to handle it. MIT identifies that since 2002 the rate at which genomes can be sequenced has been doubling every 4 months or so. longitudinal data that clearly illustrates positive patient outcomes. and life sciences companies will increasingly work with these organizations and payers to optimize payer-rebate models and increase the role of diagnostics in pinpointing the most effective treatments. financial data. In life sciences.7 In conference speeches and trade press articles.9 Medco. problems whose resolution was never attempted before. A key factor for being able to do this successfully is the ability to generate real-world evidence through data and analytics.8 Being able to combine information from EMRs and e-prescribing will enable tracking of a patient’s outcomes over the care continuum and is critical to the provider’s ability to demonstrate outcomes that result from care for which they should be reimbursed. is a clear example of this trend. The outcome-based reimbursement models of the future will require complete. 6 . Health insurance exchanges (HIEs) will partially control shared data and are projected to move toward this shared model. and electronic patient-reported data to deliver real insights into optimizing care management and evaluating which therapies provide the highest overall value to patients and healthcare systems. What’s emerging is a new world of horizontally scaling. Sanofi intends to use this data to improve treatment development and meet the needs of insurers and regulators to obtain compelling evidence of a drug’s benefits. whereas computing power has doubled only every 18 months.

10 Assessing patients on the basis of genetic information will improve outcomes for the patient and enable the development of more targeted treatments. including genetic profiling. will enable biopharma companies to target participants more effectively for clinical trials and treatment. Life Technologies and Illumina have already announced availability of next-generation gene-sequencing machines capable of delivering results in a few hours for most comprehensive genetic diagnostic tests. As a starting point. most enterprises will need to build better data architecture skills. Technology leaders will be expected to enable life sciences companies to bring together data management and analytics capabilities to leverage the value of real-world data. To prepare for this. 7 .Technology Vision 2012 What it means for Life Sciences In a future in which personalized (or precision) medicine has become a reality. forward-thinking technology leaders should identify “data owners” in the business. CIOs will have to think in terms of new skills they will need within their organizations. They should work with them to identify business processes that can begin to leverage data as a platform and identify the “burning platforms” among the organization’s business processes that can become the vehicles for change and the testing grounds for new value-added data services. new sources of information. provided that the industry can overcome data-privacy and cost concerns.

academic institution and research lab partners. Standards in R&D are maturing.13 Relatively few life sciences companies have been able to fully define data lifecycle Traditionally. and NCI standards. which can yield findings at lower cost and with lower risk. the voluntary global healthcare user group GS1 is developing global standards for patient safety and supply-chain efficiency that will enable track-and-trace capabilities for targeted recall systems. But if data can be decoupled. 8 . Data services will also have uses beyond the organization’s boundaries as companies outsource parts of their operations and more third-party data-service providers emerge. better control of product security. and improved inventoryreplenishment mechanisms. enterprises will find opportunities to use it in many different ways to unlock far more of its potential value. For example.Technology Vision 2012 What it means for Life Sciences New data services will unlock the value of sharing across the extended enterprise Organizations are actively hunting for other useful data—outside their organizations as well as inside—while keeping their eyes open for opportunities to share their data. people within the organization will find innovative and valuable uses for them. CDISC. data has been organized chiefly around applications and used in silos.12 Further. The move to industrialized data services will be enabled by mature master data and meta-data management and industry data standards. Data services establish data as an asset that is published and available to be used for various purposes. establishing data services enables the use of clinical-trial data in trial simulations. As data services become available. in sales and marketing. Pharmaceutical companies are already defining data services that integrate clinical data across research partners (see sidebar). driven largely by the FDA’s BRIDG program to unify HL7. Data services will enable R&D organizations to collate and correlate data from contract research organizations (CROs). and the concept of data services will enable companies to break down traditional boundaries and will support efficient new operating models. in R&D. and public health institutes to create deep insights into new solutions and better metrics on the efficacy and safety of drugs and devices in the pipeline. physician data provided as a service may be used to simplify compliance reporting.

Outsourcing of clinical trial execution is becoming commonplace in pharmaceutical companies. academic Institutions. This change also requires a re-architecting of organizational roles to gear the enterprise toward data services.Technology Vision 2012 What it means for Life Sciences management—that is. will accelerate companies toward the notion of centralized data management. and trends that inform more intelligent study execution. who transforms it. and strategic management of its relationships with regulators. The data-sharing model. and teaching hospitals) will be aggregated and used to provide deep insights. monitoring of progress to increase productivity. The change to the operating model allows the company to focus its scientific brainpower on timely analysis of the data.11 Data from clinical trials that is stored in the different systems operated by the various external trial partners (CROs. by its nature. to understand who in their organization contributes to the data. They can then engage business leadership in discussions on the value of data and prioritize the evolution to data services. By creating a layer of abstraction between data and applications. and who consumes it. visualizations. 9 . One major company is taking the opportunity to implement a new operating model with the help of data aggregation services developed by Accenture and based on the Oracle Life Sciences Data Hub. Forward-thinking technology leaders should work with business colleagues to take the first step to understand which data is valuable to the enterprise and then to explore its lifecycle and its security and compliance attributes. IT has the opportunity to standardize and industrialize data management.

10 .15 Despite this some life sciences companies have been successful in engaging customers. People are increasingly likely to use social media as part of their healthcare routines. more than two-thirds of U. Jive.16 Sanofi has also emerged as a social media leader by building a community for diabetes sufferers on Facebook who connect and share on-line to improve their experience with the disease. providing support. incentives. Life sciences companies can do this only by working in a broader ecosystem that will not only drive efficiency but also be a source of innovation. and companies can listen to the voices of patients through The key challenge for the life sciences industry is to address increasing healthcare costs. a multichannel approach provides continuity and consistency across all interactions with customers. is therefore critical. and sponsorship from company leadership. and sales forces and call centers can use channels to medical experts to support their dialogues with physicians. whether to find further information by using social tools or to register complaints. consumers seek medical advice via the Internet and social media. Sanofi has used the community to set priorities for its annual Data Design Diabetes Innovation Challenge to come up with initiatives using big data to help those living with the disease and also to help it to refine its offerings for disease sufferers.14 Social media is a highly sensitive area for biopharma companies and most medical technology companies.S. According to a recent Accenture study. Typically. Those changes need to be addressed through a mixture of steps: embedding social media into processes. the life sciences industry is still feeling its way with social media. enabled by Social IT. Greater familiarity and use of social media internally will also build confidence as companies take their social media efforts outside of the organization to engage with patients and healthcare practitioners. Sales teams can share insights and successes across locations. While the FDA has provided recent guidance on how companies should respond to unsolicited requests in social media forums. Companies have started investing in tools like Yammer. which are bound by strict marketing regulations and face uncertainties regarding how they can engage patients and healthcare practitioners in social media forums. and ensuring measurement of initiatives to gauge success.17 Patient and physician forums are also important channels that allow companies to listen to consumers and provide customer service. but cultural changes are needed to drive adoption of social media internally within organizations. consumers are looking to engage with physician or patient communities. GE created a digital campaign (healthymagination) that aimed to improve its’ image as a driving force in health. and Salesforce.com (with its Chatter feature) to build a strong internal social fabric. such as the iBGStar personal glucose monitor and smart phone Apps. Marketing teams can share early feedback on products with the R&D group. both internally and externally. Effective collaboration.Technology Vision 2012 What it means for Life Sciences Social-driven IT provides industrywide opportunities to address escalating healthcare costs Social-driven IT can foster stronger collaboration and forge links that result in innovation within a life sciences company.

11 . and companies will need to adapt their approaches accordingly. While life sciences companies’ use of social media externally will be addressed primarily by brand teams working with agency partners. this could provide a valuable source of information and opportunities to contribute to research. technology leaders can help by providing tools as part of digital platforms that help manage high-quality.com and www. consistent content and enable reuse. Imagine a marketplace for research that enabled physicians and life sciences companies to share peer-to-peer information. R&D is.cn (the leading social media website for physicians in China). They can also build a reputation as a good citizen through engaging through social media to provide customer service.sermo.Technology Vision 2012 What it means for Life Sciences popular online community forums like www. a collaborative process.haoyisheng. which can reduce the risk of R&D failure and public health scares caused by flawed research.com and www.sharecare.com and those of healthcare practitioners through forums such as www. Forums of academics and researchers will be encouraged to participate in and review research findings. where conferences and networks are less well developed. and social IT has a significant role to play in R&D-related collaboration within life sciences companies and with external researchers. In emerging markets in particular. by its nature. such as lab notebooks. Use of social media does vary by therapy area and patient demographics.patientslikeme. which could lead to better positioning of their solutions and build invaluable caring and trustbased customer relationships. and they can encourage effective use of social media inside the organization by providing tools and encouraging cultural change to drive adoption. which could be rated. Social IT will be integrated into R&D processes and with technologies. for example by responding and directing patients to appropriate channels for their questions and complaints. Relevant insights from such forums can help the industry to understand customer perspectives and problems and current treatment trends and patterns.

000 users in hundreds of locations worldwide use the platform.18 In another example. is actively moving into the PaaS space. low-cost experiments. the traditional direct sales force model is no longer justifiable in terms of cost and revenue impact and is challenged by a digital revolution that is changing the way healthcare professionals interact with companies. such as web portals. without having to bear the costs or delays of deploying traditional in-house enterprise solutions. cloud solutions for the sales and marketing area are witnessing a rapid uptake. to support its more than 90. call centers. 12 . offering platform capabilities to augment their offerings. including Gmail and Google Docs. With life sciences companies needing to focus capital spending in growth areas. GlaxoSmithKline. it becomes possible to innovate rapidly and react to market shifts. Veeva. deploying Exchange. Salesforce.com platform is likely to grow as companies look to make the most of the With the rapid and burgeoning uptake of iPad and tablet devices for the sales force. Providers with rich catalogues of business services—such as the SaaS vendors—are pushing down the stack. The lower investment required enables more experimentation. Companies are increasingly looking at how they can use SaaS solutions in a way that complements mature in-house systems to integrate multiple channels. for example. enabling Roche’s strategic collaboration strategy without requiring large expenditures and potentially disruptive upgrades. SharePoint. as life sciences companies focus on growth in emerging markets. vertical vendors serving life sciences customers have built dedicated service centers that offer more stringent physical and virtual security than life sciences firms have in-house. time sensitive. There has been a proliferation of apps and sales force enablement tools provided in the cloud aimed at providing rapid. however signs indicate that the cloud market is adapting to meet the specific needs of life sciences. Private cloud solutions can provide some of the benefits while overcoming IP concerns and vertical cloud services targeted specifically at the life sciences industry are overcoming regulatory hurdles. multichannel CRM solution based on the force. has adopted Microsoft’s Office 365. and Office Live Meeting. Roche intends to move from two separate email and calendaring systems to a cloud-based platform that it believes will continue to evolve in a socially focused way. With PaaS. Office Communicator. content rich capabilities to enhance and compliment the field force productivity. Similar to cloud services in the financial services sector. More than 100. for example. Software-as-a-Service (SaaS) enables them to leapfrog from basic capabilities onto technologies that support a more cost-effective multichannel model.000 employees globally. A company can. For more mature markets. and use of the force.Technology Vision 2012 What it means for Life Sciences PaaS will shift the focus on cloud from cost-cutting to business agility and innovation Concerns about intellectual property (IP) protection and extensive regulatory requirements have so far limited application of the cloud largely to sales and marketing functions and pilot R&D programs. for example. As a result.20 Platform as a Service (PaaS) (see side bar for definition) enables the organization to launch and learn from quick. The agility that PaaS creates will enable and encourage business innovation. which will result in more innovation. Roche recently announced it was moving over to Google’s cloud-based productivity and collaborative applications. the cloud provides an ideal opportunity to switch capital-intensive IT to a more variable operational cost model.19 In sales and marketing. sales forces. a cloud-based. Deployment targeted 30% savings in operational costs as well as benefits from better scalability in response to business change.com platform but specialized for the biopharma industry. has gained significant traction with biopharma companies. open up new features and functions to small groups of users. and social media.

therefore. PaaS “app stores. Gartner predicts that by 2014.Technology Vision 2012 What it means for Life Sciences investment already made in the platform and force. Accenture believes that PaaS has greatest applicability in the business services that will require a significant level of innovation. 13 . Amazon EC2. Hybrid cloud enables on-premise and off-premise services to be seamlessly mixed. where services can be moved on-premise or off-premise and capacity can be added at times of increased demand. have both adopted Amazon’s Elastic Compute Cloud (EC2) Platform to conduct analysis including simulation models in early discovery that have been operational within hours. In selecting PaaS platforms.” such as Salesforce’s AppExchange. experimentation. will be another source of innovation as Apple’s app-store model is replicated. Google App Engine. PaaS is a complete. pre-integrated platform offering for the development of general-purpose business applications. It offers opportunities that support an experimental approach. and. incurred significant capital costs and potentially delayed getting products to market. A platform can be used to develop. and determine where PaaS fits in the overall IT strategy. In terms of life sciences R&D. PaaS offerings facilitate the deployment of applications without the cost and complexity of buying and managing the underlying hardware and software and providing hosting capabilities.com. iteration. and Microsoft Azure. 25% of life sciences R&D organizations will pilot discovery research applications using cloud computing. development. identify platforms that will be used to support business needs.com licenses. in some areas they are still quite immature. Rather. they should explore the option of adopting a hybrid cloud approach (see side-bar). PaaS tools for management. and run business applications rapidly. but between enterprises. flexibility. for example. whereas traditional in-house implementations would have taken weeks. test. Typical examples of PaaS platforms include Salesforce force.21 Eli Lilly and Pfizer.22 Even though platform technologies are evolving rapidly. and measurement are not yet at the level of those that IT departments work with on-premise. Life sciences organizations should evaluate the most valuable business processes (potential as well as current). organizations need to be mindful that they do not get locked into platforms.

and communications channels so that they can bring in relevant capabilities as needed. the platform might compare information packets. We predict that to better understand their risks and to detect attacks. Existing approaches that focus on perimeter-based security are inadequate for handling these challenges. Cloud. moving from simply maintaining a list of systems administrators to flagging the creation of new systems administrator positions. implement. security leads have to think and act in terms of orchestrating security resources and responses across systems. and mobility are increasing the potential threats. moving from monitoring “who has access to which assets” to monitoring “trends of unauthorized access attempts to specific assets. they must develop “data-centric” mindsets that leverage new data platform concepts to design. First.Technology Vision 2012 What it means for Life Sciences Growing security concerns will result in a paradigm shift toward data-centric security platforms Organizations are becoming more vulnerable because they are increasingly connected. and frequency and intensity of breaches. its products and research. and run systems. providers. To deal with the complex and ever-changing array of threats. for instance. business imperatives are increasing the need to share information across the extended enterprise and intensifying pressure on IT. IT organizations need to move from the current focus on a hardened perimeter-based security to a new paradigm that recognizes that some attacks will get through and that organizations will need to monitor for security compromises in the first place. The industry also deals with highly sensitive and personal patient data and increasingly stringent regulations. reacting to them when they occur in a way that is commensurate with the risks they pose to the business. the same packets going to different hosts could indicate that information is being echoed to a snooping threat.” That means. In another instance. It also calls for a shift from an asset-focused view to a process-specific and data-centric view of enterprise activities. triggering a compliance check. social media. At the same time. organizations must move from “monitoring” to “understanding”. connected plant and buildings. 14 . Third. IT leaders must be aware of the host of nontraditional “attack surfaces” that threaten their organizations today.” As an example. organizations will increasingly turn to data platform The life sciences industry is highly focused when it comes to protecting proprietary and confidential information about. Second. points and complexity of attack. companies could use the data platform to help identify a possible internal threat by analyzing the activity patterns of a suspect employee’s time spent downloading confidential data. from “collection of data” to “visualization of behaviors and anomalies. Three core security issues must be addressed.

Technology Vision 2012 What it means for Life Sciences technologies—technologies that provide data access and aggregation via services. They should identify the most critical business systems and data sets and assess their vulnerability. and then work together with various infrastructure. flexible security a priority when IT systems are being designed and developed. they should assess the vulnerability of nontraditional connected systems and audit basic processes such as patch management and user access. The vision of the data-centric security platform is just that: a vision. They should work with business peers to articulate risks and tolerance. Mastering risk and figuring out the big picture makes data and analytics the two new core competencies of the security organization. In the meantime. and service providers to close the vulnerability. At the management level. Further. IT leaders should establish processes that make robust. Chief information security officers will need to tap into pools of niche skills to solve the problem. IT security chiefs will also need to demonstrate that they can rapidly marshal security resources. at speed. orchestration will involve identifying and accessing the right internal and external resources when needed and getting them to work in concert. 15 . The data platform will handle secure access to large volumes of fast-changing data—orders of magnitude greater in scale than traditional log analysis. application.

 Bolster data services and management capabilities Identify “data owners” in the business and work with them to understand business processes that can begin to leverage data in the platform. 4. ensuring a sponsor from company leadership. and following through with measurement. incentivizing behaviors. most enterprises will need to build better data architecture skills. D  efine a cloud strategy Cloud providers are rapidly developing vertical offerings to meet the specific needs of the life sciences industries. current geo-economic factors and strategy. developing a comprehensive action plan. and technology leaders should consider some priority areas for action: 1. 5. dependency and ownership and the resulting insights can be used to help to prioritize the data services that will be important to the business and to establish a roadmap for implementing data services. C  hange the security paradigm Change the security mindset from “perimeter-based security” to “orchestrated security processes” around data platforms. Collaboration is critical to this industry. Life sciences companies need to have a strategy that enables them to drive adoption.Technology Vision 2012 What it means for Life Sciences The next steps for life sciences technology leaders Accenture’s annual Technology Vision provides a perspective on the future of technology likely to shape our industry in the next three to five years.  Embed use of social technologies across the organization Many life sciences companies have invested in technology but adoption is patchy within the enterprise and with partners.1 2. 16 . providing support.  Define an Information Strategy Identification of the most critical information that drives the highest value across the business is key to addressing many of the trends outlined in the Technology Vision 2012. An Information Strategy highlights quality. This is a significant shift in the role of IT requiring a rethink 6. As a starting point. and technology leaders should have a vision and roadmap for social collaboration and plans for increasing adoption by prioritizing and embedding social technologies into processes. Consider Accenture’s suggested actions for embracing each trend over a 12-month time frame.  Prioritize the technology trends Determine the trends that will have the biggest impact on the industry and your organization based on your business drivers. which manages risk commensurate with value and recognizes that organizations must anticipate and monitor for security compromises. IT leaders should be looking at the role they will play in enabling cloud adoption and positioning themselves as an enabler or integrator of internally and externally provided services. 3. Think in terms of new skills that will be needed in the organization.

Technology Vision 2012 What it means for Life Sciences Accenture Technology Vision 2007-2012 17 .

Gavin Michael Chief Technology Innovation Officer g.com www.com Dr.com Michael Biltz Director.kurth@accenture.Technology Vision 2012 What it means for Life Sciences Contacts: Anne O’Riordan Global Life Sciences Industry Managing Director +85 2 2249 2643 anne.com Rajesh Bhasin Accenture Life Sciences Senior Manager +44 207 844 4637 rajesh. Accenture Technology Vision michael.accenture.michael@accenture. Kurth Director.bhasin@accenture.com Scott W.com/lifesciences 18 .j.biltz@accenture.c.oriordan@accenture. Accenture Technology Vision scott.

” June 22. “Accenture Helps the Alzheimer’s Association Develop a Location Management Strategy.  Accenture.  Reuters.sharedhealth. Amazon Web Services.” 2010 4. 2012 11.veevasystems. “Pfizer Israel: Healthcare Engagement Strategy 2012 ‘Time & Place’ Award. “Microsoft Online Services Available Worldwide. “How Sanofi Is Writing The Social Media Rules For Big Pharma Without Running Afoul Of The FDA.” January 10.  Microsoft press release.  CNET.  Life Technologies press release. 2012 5.  InformationWeek. “The Roche Group Goes Google. “Predicts 2012: Life Science Companies Will Need to Capitalize on Investments Made in Restructuring.. Consumers Seek Medical Advice Via the Internet and Social Media.  Gartner. Shared Health website: http://www. 2012 6. Veeva Systems website: http://eu. “Translating the New FDA Social Media Guidance.com 9.  InPharm. “Accenture Technology Vision 2012.  Accenture.  Dose of Digital.  GE Reports.” February 3. “AWS Case Study: Pfizer. Healthcare Engagement Strategy.  Journal of the American Medical Informatics Association.  MIT News.” May 3.” March-April 2008 13. “New iPad First Tablet with Bluetooth 4. Inc.” May 22. “Boehringer Collaborates for Online ‘Beyond Pill’ Plan. “The BRIDG Project: A Technical Report. “Accenture Achieves Oracle PartnerNetwork Specialization for Oracle Life Sciences Data Hub.” February 16. 2010 15. “InformationWeek 500: Eli Lilly Ties Future To Cloud.” January 2012 2. 2011 10. “Howcast-GE Healthymagination Case Study.  Clarityn.S. “Facebook for the Body: Your Organs May Soon Report Their Status Over New Generation of Wireless Medical Sensors. “Medco.  Accenture. 2010.” December 15. 2012 12.” March 2.” November 16. “Illumina Introduces the HiSeq 2500.  Accenture. 2012 7. 2012 18. Accenture Study Finds. GS1 website: http://www. 2012 16.  Fast Company.org/healthcare 14.” July 10. Illumina press release. 2012 8.References: 1.” January 11. 2009 19. 2012 19 .gs1.” January 4.  Google Enterprise Blog.” January 10. Sanofi Drug Deal Brings Payor View to R&D.” 2010 17. “Searching Genomic Data Faster.  Howcast.” August 20. 2012.” July 11. “Life Technologies Introduces the Benchtop Ion Proton Sequencer. 2012 20. 2012 3.0: Should You Care?” March 9. “More Than Two-Thirds of U.com/buzz/customers/ 21. Clarityn Allergy Pollen Forecast App. 2011 22.” September 14.

and High Performance Delivered are trademarks of Accenture. and extensive research on the world’s most successful companies. 31. Copyright © 2012 Accenture. 2011. belong to their respective owners. All rights reserved. medical products. with more than 244.About Accenture Accenture is a global management consulting.accenture. its logo. Combining unparalleled experience. Rights to trademarks referenced herein. including pharmacovigilance and regulatory outsourcing.5 billion for the fiscal year ended Aug. technology and outsourcing services across the entire life sciences value chain. distributors. including commercial services. technology services and outsourcing company. Supply Chain and Manufacturing Optimization. The company generated net revenues of US$25.com. . About Accenture’s Life Sciences Practice Our Life Sciences industry group works with pharmaceuticals. comprehensive capabilities across all industries and business functions.000 people serving clients in more than 120 countries. Accenture. regulators. wholesalers and other companies to help bring life-enhancing health solutions to people around the globe. Our key offerings include: Research and Development. other than Accenture trademarks. biotechnology. analytics and digital marketing. We provide consulting. Accenture collaborates with clients to help them become high-performance businesses and governments. We disclaim proprietary interest in the marks and names of others. from large-scale business and technology transformation to post-merger integration. Its home page is www. medical technology. and Marketing and Sales.

Sign up to vote on this title
UsefulNot useful